Adaptive Biotechnologies Financials
ADPT Stock  USD 7.05 0.09 1.29% 
Adaptive  Select Account or Indicator 
With this module, you can analyze Adaptive financials for your investing period. You should be able to track the changes in Adaptive Biotechnologies individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Adaptive Most Recent Estimates
EPS Estimate Next Quarter (0.32)  Diluted Eps (1.40)  EPS Estimate Current Year (1.23)  EPS Estimate Next Year (1.01)  EPS Estimate Current Quarter (0.38) 
Understanding current and past Adaptive Biotechnologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Adaptive Biotechnologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Adaptive Biotechnologies' assets may result in an increase in income on the income statement.
The financial analysis of Adaptive Biotechnologies is a critical element in measuring its lifeblood. The essential information of the daytoday investment outlook for Adaptive Biotechnologies includes many different criteria found on its balance sheet. For example, investors should never minimize Adaptive Biotechnologies' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to reinvest extra cash. Any individual investor needs to monitor Adaptive Biotechnologies' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Adaptive Biotechnologies.
Cash and Equivalents 

Evaluating Adaptive Biotechnologies' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Adaptive Biotechnologies' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Adaptive Biotechnologies' relative financial performance
Chance Of Distress
Less than 13
100  0 
Adaptive Biotechnologies Corp has less than 13 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Adaptive Biotechnologies stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Adaptive Biotechnologies' odds of distress score SHOULD NOT be confused with the real chance of Adaptive Biotechnologies Corp filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Adaptive is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including shortterm and longterm historical volatility. Other factors considered include Adaptive Biotechnologies' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More InfoThe data published in Adaptive Biotechnologies' official financial statements usually reflect Adaptive Biotechnologies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Adaptive Biotechnologies. For example, before you start analyzing numbers published by Adaptive accountants, it's critical to develop an understanding of what Adaptive Biotechnologies' liquidity, profitability, and earnings quality are in the context of the Life Sciences Tools & Services space in which it operates.
Please note, the presentation of Adaptive Biotechnologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adaptive Biotechnologies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Adaptive Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adaptive Biotechnologies Corp. Please utilize our Beneish M Score to check the likelihood of Adaptive Biotechnologies' management manipulating its earnings.
Adaptive Biotechnologies Company Summary
Adaptive Biotechnologies competes with Valneva SE, Dominari Holdings, Home Depot, Johnson Johnson, and Verizon Communications. Adaptive Biotechnologies Corporation, a commercialstage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 858 people.Specialization  Health Care, Pharmaceuticals, Biotechnology & Life Sciences 
Instrument  USA Stock View All 
Exchange  NASDAQ Exchange 
ISIN  US00650F1093 
CUSIP  00650F109 
Location  Washington; U.S.A 
Business Address  1165 Eastlake Avenue 
Sector  Life Sciences Tools & Services 
Industry  Health Care 
Benchmark  NYSE Composite 
Website  www.adaptivebiotech.com 
Phone  206 659 0067 
Currency  USD  US Dollar 
You should never invest in Adaptive Biotechnologies without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Adaptive Stock, because this is throwing your money away. Analyzing the key information contained in Adaptive Biotechnologies' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Adaptive Biotechnologies Key Financial Ratios
Generally speaking, Adaptive Biotechnologies' financial ratios allow both analysts and investors to convert raw data from Adaptive Biotechnologies' financial statements into concise, actionable information that can be used to evaluate the performance of Adaptive Biotechnologies over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Adaptive Biotechnologies reports annually and quarterly.Return On Asset  (0.15) %  
Profit Margin  (1.06) %  
Operating Margin  (1.05) % 
Adaptive Biotechnologies Key Balance Sheet Accounts
2018  2019  2020  2021  2022  2023 (projected)  
Total Assets  332.69 M  912.3 M  1.12 B  923.34 M  856.62 M  885.43 M  
Current Assets  180.72 M  612.69 M  726.91 M  402.75 M  562.15 M  555.47 M  
Assets Non Current  151.97 M  299.61 M  389.5 M  520.6 M  294.47 M  329.96 M  
Cash and Equivalents  55.09 M  98.71 M  125.57 M  141.2 M  92.43 M  106.38 M  
Deferred Revenue  13.4 M  280.33 M  236.94 M  179.21 M  122.71 M  146.28 M  
Inventory  7.84 M  9.07 M  14.06 M  19.26 M  14.45 M  14.31 M  
Investments  109.99 M  585.73 M  683.36 M  431.14 M  408.17 M  440.05 M  
Investments Current  109.99 M  480.29 M  564.83 M  214 M  408.17 M  396.63 M  
Total Liabilities  29.94 M  341.26 M  373.15 M  319.24 M  392.52 M  349.58 M  
Current Liabilities  22.8 M  78.31 M  105.2 M  113.81 M  109.79 M  101.29 M 
Adaptive Biotechnologies Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out noncash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Adaptive Biotechnologies' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
2018  2019  2020  2021  2022  2023 (projected)  
Consolidated Income  (46.45 M)  (68.61 M)  (146.23 M)  (207.3 M)  (200.37 M)  (205.64 M)  
Cost of Revenue  19.67 M  22.27 M  22.53 M  49.3 M  57.91 M  48.56 M  
Gross Profit  35.99 M  62.8 M  75.85 M  105.04 M  127.4 M  108.53 M  
Net Income  (46.45 M)  (68.61 M)  (146.23 M)  (207.28 M)  (200.19 M)  (205.46 M)  
Operating Expenses  85.75 M  141.19 M  228.67 M  314.01 M  327.58 M  284.77 M  
Operating Income  (49.76 M)  (78.39 M)  (152.82 M)  (208.97 M)  (200.19 M)  (205.45 M)  
Revenues  55.66 M  85.07 M  98.38 M  154.34 M  185.31 M  157.09 M 
Adaptive Biotechnologies Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Adaptive Biotechnologies. It measures of how well Adaptive is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Adaptive Biotechnologies brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Adaptive had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Adaptive Biotechnologies has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in nonbusiness activities like paying off debt or making acquisitions.
2018  2019  2020  2021  2022  2023 (projected)  
Capital Expenditure  (6.3 M)  (11.2 M)  (18.8 M)  (61.75 M)  (16.35 M)  (17.64 M)  
Depreciation Amortization and Accretion  6 M  7.79 M  11.74 M  20.98 M  28.15 M  22.58 M  
Net Cash Flow or Change in Cash and Cash Equivalents  (30.27 M)  43.62 M  26.86 M  15.63 M  (48.77 M)  (50.06 M)  
Issuance Purchase of Equity Shares  1.27 M  324.91 M  293.91 M  26.72 M  7.89 M  8.1 M  
Net Cash Flow from Financing  1.25 M  319.92 M  293.59 M  27.15 M  132.26 M  149.14 M  
Net Cash Flow from Investing  736 K  (481.7 M)  (117.04 M)  181.21 M  2.9 M  3.13 M  
Net Cash Flow Investment Acquisitions and Disposals  7.04 M  (470.5 M)  (98.24 M)  242.96 M  19.25 M  20.77 M  
Net Cash Flow from Operations  (32.26 M)  205.4 M  (149.68 M)  (192.73 M)  (183.94 M)  (188.79 M)  
Share Based Compensation  11.15 M  13.12 M  24.76 M  43.25 M  55.48 M  44.13 M 
Adaptive Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adaptive Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adaptive Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adaptive Biotechnologies competition to find correlations between indicators driving Adaptive Biotechnologies's intrinsic value. More Info.Adaptive Biotechnologies Corp is number one stock in working capital category among related companies. It is number one stock in retained earnings category among related companies . Adaptive Biotechnologies Working Capital is comparatively stable at the moment as compared to the past year. Adaptive Biotechnologies reported Working Capital of 452.36 Million in 2022. Comparative valuation analysis is a catchall model that can be used if you cannot value Adaptive Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Adaptive Biotechnologies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the pricetoearnings (P/E), pricetobook (P/B), pricetosales (P/S), pricetocash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Adaptive Biotechnologies' earnings, one of the primary drivers of an investment's value.Adaptive Biotechnologies Systematic Risk
Adaptive Biotechnologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a welldiversified portfolio. Adaptive Biotechnologies volatility which cannot be eliminated through diversification, requires returns over the riskfree rate. Over the long run, a welldiversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a tradeoff between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was two with a total number of output elements of fiftynine. The Beta measures systematic risk based on how returns on Adaptive Biotechnologies correlated with the market. If Beta is less than 0 Adaptive Biotechnologies generally moves in the opposite direction as compared to the market. If Adaptive Biotechnologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Adaptive Biotechnologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Adaptive Biotechnologies is generally in the same direction as the market. If Beta > 1 Adaptive Biotechnologies moves generally in the same direction as, but more than the movement of the benchmark..
About Adaptive Biotechnologies Financials
What exactly are Adaptive Biotechnologies Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Adaptive Biotechnologies' income statement, its balance sheet, and the statement of cash flows. Potential Adaptive Biotechnologies investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may use each financial statement separately, they are all related. The changes in Adaptive Biotechnologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adaptive Biotechnologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Steps to analyze Adaptive Biotechnologies Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debttoequity ratio because this number will tell you how much risk it has. If a company such as Adaptive Biotechnologies is not taking on any additional risks, its debttoequity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Adaptive has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Adaptive Biotechnologies' financials are consistent with your investment objective using the following steps: Review Adaptive Biotechnologies' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
 Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
 Study the cash flow inflows and outflows to understand Adaptive Biotechnologies' liquidity and solvency.
 Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
 Compare Adaptive Biotechnologies' financials to those of its peers to see how it stacks up and identify any potential red flags.
 Use valuation ratios to evaluate the company's financials using commonly used ratios such as the pricetoearnings (P/E) ratio, pricetosales (P/S) ratio, and enterprise valuetoearnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Adaptive Biotechnologies' stock is overvalued or undervalued.
Adaptive Biotechnologies June 2, 2023 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Adaptive Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adaptive Biotechnologies Corp. We use our internallydeveloped statistical techniques to arrive at the intrinsic value of Adaptive Biotechnologies Corp based on widely used predictive technical indicators. In general, we focus on analyzing Adaptive Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adaptive Biotechnologies's daily price indicators and compare them against related drivers.
Information Ratio  (0.03924)  
Maximum Drawdown  21.79  
Value At Risk  (6.83)  
Potential Upside  6.42 
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Idea Analyzer module to analyze all characteristics, volatility and riskadjusted return of Macroaxis ideas.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing  
Money Managers Screen money managers from public funds and ETFs managed around the world  
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated  
Idea Optimizer Use advanced portfolio builder with precomputed micro ideas to build optimal portfolio  
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins  
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk  
Portfolio Rebalancing Analyze riskadjusted returns against different time horizons to find assetallocation targets 
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40)  Revenue Per Share 1.289  Quarterly Revenue Growth (0.025)  Return On Assets (0.15)  Return On Equity (0.40) 
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.